ORCA-010
Localized Prostate Cancer
Phase I/IIaActive
Key Facts
About ORCA Therapeutics
ORCA Therapeutics is a private, pre-revenue biotech developing novel oncolytic virus therapies for prostate cancer. The company's core technology, the T1 platform, aims to create adenoviruses with significantly higher oncolytic potency compared to current standards. Its lead program, ORCA-010, is in a Phase I/IIa dose-escalation study in Canada for treatment-naïve, localized prostate cancer patients, representing a direct intratumoral approach in an early-stage setting. The company leverages partnerships and has received Horizon2020 grant funding to advance its research.
View full company profileTherapeutic Areas
Other Localized Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Karolinska Institutet Prostate Cancer IRE Study | AngioDynamics | Randomized Controlled Trial |
| SBRT for Prostate Cancer | Accuray | Clinical Adoption |
| TULSA-PRO® | Profound Medical | Commercial |